Abzena, the leading Partner Research Organization (PRO) providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs) has announced the appointment of Dr. Petra Dieterich, DPhil, MBA, as scientific lead. Reporting to Abzena’s chief technology officer Dr. Louise Duffy, Dr. Dieterich will use her extensive technical knowledge and leadership experience to support Abzena’s successful drug development and manufacturing operations, ultimately assisting in getting more successful treatments to patients. Dr Louise Duffy, chief technology officer at Abzena, said: “Petra is a valuable addition for both the Abzena team and our clients. “She has held several leadership positions and
The post Abzena announces appointment of Petra Dieterich as Scientific Lead appeared first on Pharma Mirror Magazine.
